Practically, these combinations are well tolerated in patients with combinations of 3 different PARPi [Olaparib (42), niraparib (43) and BGB-290 (44)] and PD-L1 or PD-1 antibodies being tested in a variety of cancer types (NCT02657889, NCT02484404 and NCT02660034). The gene discussed is CD274; the disease is cancer.